CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| 10404 | ETCTN | A Phase 1 Trial of the ATR Inhibitor BAY 1895344 in Combination with Cisplatin and with Cisplatin Plus Gemcitabine in Advanced Solid Tumors with an Emphasis on Urothelial Carcinoma | Adult CIRB - Early Phase Emphasis | Available to Open |
| 9910 | ETCTN | A phase 1 trial of MLN0128 (TAK-228) in combination with osimertinib (AZD9291) in advanced EGFR mutation positive non-small cell lung cancer (NSCLC) after progression on a previous EGFR tyrosine kinase inhibitor | Adult CIRB - Early Phase Emphasis | Available to Open |
| 10327 | ETCTN | A Phase 1 Trial of MLN0128 (sapanisertib) and CB-839 HCl (telaglenastat) in Advanced NSCLC Patients | Adult CIRB - Early Phase Emphasis | Available to Open |
| 9676 | ETCTN | A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients with Advanced Solid Tumors | Adult CIRB - Early Phase Emphasis | Available to Open |
| 10389 | ETCTN | A Phase 1 Trial Combining WEE1 Inhibitor Adavosertib (AZD1775) with Radiation Therapy for Metastatic or Inoperable and Ineligible for Definitive Chemoradiation Esophageal and Gastroesophageal Junction Cancer | Adult CIRB - Early Phase Emphasis | Available to Open |
| 10449 | ETCTN | A Phase 1 Study of ZEN003694 in Combination with Binimetinib in Solid Tumors with RAS Pathway Alterations and Triple Negative Breast Cancer | Adult CIRB - Early Phase Emphasis | Available to Open |
| 10605 | ETCTN | A Phase 1 Study of ZEN003694 (ZEN-3694) in Combination with Cetuximab and Encorafenib in Patients with Refractory BRAF V600E Metastatic Colorectal Cancer | Adult CIRB - Early Phase Emphasis | Available to Open |
| ADVL1315 | COG | A Phase 1 Study of the VEGF Receptor Tyrosine Kinase Inhibitor Axitinib (INLYTA; 123101) in Children with Recurrent or Refractory Solid Tumors | Pediatric CIRB | Completed |
| 10528 | ETCTN | A Phase 1 Study of the Polymerase Theta (POLθ) Inhibitor Novobiocin in BRCA-mutant and Other DNA Damage Repair-Deficient Solid Tumors | Adult CIRB - Early Phase Emphasis | Available to Open |
| 9782 | ETCTN | A Phase 1 Study of Talazoparib (BMN 673) in Combination with Carboplatin and Paclitaxel in Patients with Advanced Solid Tumors | Adult CIRB - Early Phase Emphasis | Completed |